In clinical trials, patients lost an average of 2% of their body weight per month for the first six months, then 1% per month for the next six months, totaling a 16% weight loss by the end of the first year
These results support important differences obtained by enzymatic inhibition versus complete deletion of the DPP4 protein
Plaintiffs allege that Eli Lilly failed to adequately warn consumers and healthcare providers about these dangers, despite adverse event reports and medical literature raising serious concerns
REFERENCES 1 Warner MA, Meyerhoff KL, Warner ME, Posner KL, Stephens L, Domino KB
Lymphadenopathy occurring during Saxenda treatment is more likely coincidental, often caused by infection, inflammation, or other unrelated conditions
Leg cramps are not listed as a recognised adverse effect in the UK Summaries of Product Characteristics (SmPCs) for GLP-1 receptor agonists, and evidence for a causal link is limited